

# Functional dairy products

Edited by  
**Tiina Mattila-Sandholm and Maria Saarela**



CRC Press  
Boca Raton Boston New York Washington, DC

WOODHEAD PUBLISHING LIMITED  
Cambridge England

# Contents

<i>List of contributors</i> . . . . .	xi
<b>1 Introduction: classifying functional dairy products</b> . . . . .	1
<i>M. Saxelin, R. Korpela and A. Mäyrä-Mäkinen, Valio Ltd, Finland</i>	
1.1 Introduction . . . . .	1
1.2 Composition of milk . . . . .	1
1.3 Fermented milk products . . . . .	2
1.4 What do we mean by functional dairy products? . . . . .	5
1.5 Examples of functional dairy products: gastrointestinal health and general well-being . . . . .	6
1.6 Examples of functional dairy products: cardiovascular health . . . . .	10
1.7 Examples of functional dairy products: osteoporosis and other conditions . . . . .	13
1.8 Future trends . . . . .	14
1.9 Sources of further information and advice: links . . . . .	15
1.10 References . . . . .	15
<b>Part I The health benefits of functional dairy products</b> . . . . .	17
<b>2 Cancer</b> . . . . .	19
<i>C. Gill and I. Rowland, University of Ulster, UK</i>	
2.1 Introduction . . . . .	19
2.2 The relationship between diet and cancer . . . . .	19
2.3 Colon carcinogenesis . . . . .	21
2.4 Colorectal cancer and dairy products . . . . .	23
2.5 Calcium . . . . .	23
2.6 Casein . . . . .	26
2.7 Whey . . . . .	28

2.8	Conjugated linoleic acid . . . . .	28
2.9	Sphingolipids . . . . .	29
2.10	Prebiotics and probiotics . . . . .	30
2.11	Mechanisms of anticarcinogenicity and antigenotoxicity for probiotics and prebiotics . . . . .	41
2.12	Future trends . . . . .	42
2.13	Sources of further information and advice . . . . .	43
2.14	Acknowledgement . . . . .	44
2.15	References . . . . .	44
<b>3</b>	<b>Coronary heart disease . . . . .</b>	<b>54</b>
	<i>J. Lovegrove and K. Jackson, The University of Reading, UK</i>	
3.1	Introduction . . . . .	54
3.2	Risk factors in coronary heart disease . . . . .	57
3.3	Relevant lipid particles . . . . .	61
3.4	Diet and coronary heart disease . . . . .	67
3.5	The effects of probiotics on coronary heart disease . . . . .	74
3.6	The effects of prebiotics on coronary heart disease . . . . .	80
3.7	The effects of synbiotics on coronary heart disease . . . . .	85
3.8	Future trends . . . . .	86
3.9	Sources of further information and advice . . . . .	87
3.10	References . . . . .	87
<b>4</b>	<b>Osteoporosis . . . . .</b>	<b>94</b>
	<i>R. Wood, Tufts University, USA</i>	
4.1	Introduction . . . . .	94
4.2	The epidemiology of osteoporosis . . . . .	94
4.3	Dairy products, calcium intake and calcium absorption . . . . .	98
4.4	Dairy products and osteoporosis . . . . .	100
4.5	Future trends: genetic markers of osteoporosis risk . . . . .	101
4.6	Future trends: redefining a nutritional prescription for optimal bone health . . . . .	102
4.7	Sources of further information and advice . . . . .	104
4.8	References . . . . .	104
<b>5</b>	<b>Probiotics and the management of food allergy . . . . .</b>	<b>108</b>
	<i>P.V. Kirjavainen, University of Turku, Finland</i>	
5.1	Introduction . . . . .	108
5.2	The mechanisms and symptoms of food allergy . . . . .	109
5.3	The prevalence of food allergy . . . . .	113
5.4	Probiotics and food allergy: the clinical evidence . . . . .	114
5.5	Mechanisms of action: gut microbiota composition and food allergies . . . . .	116
5.6	Infant development and allergic sensitisation . . . . .	119
5.7	Selecting the right probiotic . . . . .	123
5.8	Conclusion and future trends . . . . .	125

5.9	Sources of further information and advice . . . . .	125
5.10	References . . . . .	126
<b>6</b>	<b>Dairy products and the immune function in the elderly . . . . .</b>	<b>132</b>
	<i>H. Gill, Massey University, Palmerston North, New Zealand</i>	
6.1	Introduction . . . . .	132
6.2	The immune system . . . . .	133
6.3	Immunosenescence . . . . .	134
6.4	Nutrition and immune function in the elderly . . . . .	137
6.5	Bovine milk and immunomodulation . . . . .	139
6.6	Milk proteins . . . . .	139
6.7	Antibodies and other protective agents in milk . . . . .	145
6.8	Fermented dairy products and probiotic LAB . . . . .	148
6.9	Immunomodulatory effects of fermented milk products and LAB . . . . .	149
6.10	Future trends . . . . .	157
6.11	References . . . . .	158
<b>7</b>	<b>The therapeutic use of probiotics in gastrointestinal inflammation . . . . .</b>	<b>169</b>
	<i>F. Shanahan, University College Cork, Ireland</i>	
7.1	Introduction . . . . .	169
7.2	Bacteria in the gut . . . . .	170
7.3	Studying gut flora . . . . .	170
7.4	Gut flora and intestinal function . . . . .	171
7.5	Gut immune function . . . . .	173
7.6	Microbial subversion of intestinal immunosensory function . . . . .	174
7.7	Bacterial translocation . . . . .	174
7.8	Intestinal bacteria and IBD . . . . .	175
7.9	Modifying the gut flora: probiotics in practice . . . . .	177
7.10	Future trends . . . . .	178
7.11	Sources of further information and advice . . . . .	179
7.12	Acknowledgement . . . . .	179
7.13	References . . . . .	179
<b>Part II</b>	<b>Functional dairy ingredients . . . . .</b>	<b>185</b>
<b>8</b>	<b>Caseinophosphopeptides (CPPs) as functional ingredients . . . . .</b>	<b>187</b>
	<i>R.J. FitzGerald, University of Limerick, Ireland, and H. Meisel, Institut für Chemie und Technologie der Milch, Germany</i>	
8.1	Introduction . . . . .	187
8.2	Structural characteristics and production of CPPs . . . . .	188
8.3	CPPs and mineral (calcium) bioavailability . . . . .	190
8.4	Human studies with CPPs . . . . .	191
8.5	Effect of CPPs on mineral uptake in specific cell systems . . . . .	192
8.6	Cytomodulatory effects . . . . .	193

8.7	Safety assessment of CPPs . . . . .	194
8.8	Potential ingredient applications of CPPs . . . . .	195
8.9	Summary and future trends . . . . .	197
8.10	References . . . . .	198
<b>9</b>	<b>Oligosaccharides . . . . .</b>	<b>203</b>
	<i>G. Boehm and B. Stahl, Numico Research Germany, Germany</i>	
9.1	Introduction . . . . .	203
9.2	Structural aspects of free oligosaccharides . . . . .	204
9.3	Physiological functions of dietary oligosaccharides . . . . .	220
9.4	Effect on intestinal flora: prebiotic role . . . . .	221
9.5	Effect on intestinal infections and mineral absorption . . . . .	224
9.6	Effect on the immune system and other physiological effects . . . . .	227
9.7	Analytical methods . . . . .	228
9.8	Future trends . . . . .	233
9.9	Acknowledgements . . . . .	233
9.10	References . . . . .	233
<b>10</b>	<b>Lactic acid bacteria (LAB) in functional dairy products . . . . .</b>	<b>244</b>
	<i>R. Fondén, Arla Foods ICS, Sweden, M. Saarela, J. Mättö and T. Mattila-Sandholm, VTT Biotechnology, Finland</i>	
10.1	Introduction . . . . .	244
10.2	Production of dairy products using LAB . . . . .	246
10.3	Dairy products with probiotic LAB . . . . .	248
10.4	The health benefits of probiotic LAB . . . . .	250
10.5	Enhancing the viability and stability of LAB . . . . .	252
10.6	Enhancing the functionality of LAB . . . . .	254
10.7	Future trends . . . . .	256
10.8	Sources of further information and advice . . . . .	257
10.9	References . . . . .	257
<b>11</b>	<b>Conjugated linoleic acid (CLA) as a functional ingredient . . . . .</b>	<b>263</b>
	<i>S. Gnädig, Y. Xue, O. Berdeaux, J.M. Chardigny and J-L. Sebedio, Institut National de la Recherche Agronomique, France</i>	
11.1	Introduction . . . . .	263
11.2	Natural sources of CLA . . . . .	263
11.3	Commercial production of CLA . . . . .	267
11.4	Analytic methods . . . . .	272
11.5	The influence of processing on the CLA content of dairy products . . . . .	273
11.6	Functional benefits of CLA: cancer . . . . .	274
11.7	Multisite anticarcinogenesis . . . . .	275
11.8	Multistage anticarcinogenesis . . . . .	277
11.9	Mechanisms of CLA anticarcinogenesis . . . . .	278
11.10	Functional benefits of CLA: lipid and protein metabolism . . . . .	281

11.11	The process of CLA metabolism . . . . .	284
11.12	Functional benefits of CLA: atherosclerosis . . . . .	286
11.13	Functional benefits of CLA: immune function . . . . .	287
11.14	Functional benefits of CLA: diabetes . . . . .	288
11.15	Conclusion and future trends . . . . .	289
11.16	References . . . . .	289
<b>Part III Product development . . . . .</b>		<b>299</b>
<b>12</b>	<b>Enhancing the functionality of prebiotics and probiotics . . . . .</b>	<b>301</b>
	<i>R. Rastall, The University of Reading, UK</i>	
12.1	Introduction . . . . .	301
12.2	The functional enhancement of prebiotics . . . . .	301
12.3	Targeted prebiotics . . . . .	305
12.4	Current manufacturing technologies for prebiotics . . . . .	307
12.5	Emerging manufacturing technologies for second generation prebiotics . . . . .	309
12.6	The functional enhancement of probiotics . . . . .	311
12.7	Conclusion and future trends . . . . .	311
12.8	References . . . . .	312
<b>13</b>	<b>Safety evaluation of probiotics . . . . .</b>	<b>316</b>
	<i>A.C. Ouwehand and S. Salminen, University of Turku, Finland</i>	
13.1	Introduction . . . . .	316
13.2	Key safety issues . . . . .	317
13.3	Identifying probiotic strains . . . . .	319
13.4	Potential risk factors: acute toxicity . . . . .	320
13.5	Potential risk factors: microbial metabolism . . . . .	320
13.6	Potential risk factors: microbial properties and binding . . . . .	323
13.7	Other potential risk factors . . . . .	325
13.8	Post-marketing surveillance . . . . .	327
13.9	Safety issues for new generation probiotics . . . . .	327
13.10	The safety of animal probiotics . . . . .	328
13.11	The current regulatory context . . . . .	329
13.12	Conclusion and future trends . . . . .	331
13.13	Sources for further information and advice . . . . .	332
13.14	References . . . . .	332
<b>14</b>	<b>Clinical trials . . . . .</b>	<b>337</b>
	<i>P. Marteau, Paris V University, France</i>	
14.1	Introduction . . . . .	337
14.2	Setting up a clinical trial: protocols . . . . .	337
14.3	Statistical analysis . . . . .	340
14.4	Ethical issues . . . . .	341
14.5	Managing a clinical trial . . . . .	343

14.6	Assessing the validity of a clinical trial . . . . .	343
14.7	Sources of further information and advice . . . . .	344
14.8	References . . . . .	344
<b>15</b>	<b>Consumers and functional foods . . . . .</b>	<b>346</b>
	<i>L. Lähteenmäki, VTT Biotechnology, Finland</i>	
15.1	Functional foods and consumers . . . . .	346
15.2	The role of health in food choice . . . . .	347
15.3	Nutritional guidelines and health claims . . . . .	349
15.4	Consumers, claims and carrier products . . . . .	350
15.5	Consumer attitudes to functional foods . . . . .	354
15.6	Future trends . . . . .	356
15.7	Sources of further information and advice . . . . .	357
15.8	References . . . . .	357
<b>16</b>	<b>European research in probiotics and prebiotics: the PROEUHEALTH cluster . . . . .</b>	<b>359</b>
	<i>T. Mattila-Sandholm, L. Lähteenmäki and M. Saarela, VTT Biotechnology, Finland</i>	
16.1	Introduction: research projects within the PROEUHEALTH cluster . . . . .	359
16.2	Developing research tools: MICROBE DIAGNOSTICS . . . . .	364
16.3	Understanding mechanisms of actions: DEPROHEALTH, PROPATH and EU MICROFUNCTION . . . . .	365
16.4	Investigating effects on health: PROGID, CROWNALIFE and PROSAFE . . . . .	368
16.5	Probiotic and prebiotic technologies: PROTECH . . . . .	371
16.6	Consumers and the perceived health benefits of probiotics . . . . .	372
16.7	Conclusions and future trends . . . . .	374
16.8	References . . . . .	375
<b>17</b>	<b>The market for functional dairy products: the case of the United States . . . . .</b>	<b>378</b>
	<i>L. Hoolihan, Dairy Council of California, USA</i>	
17.1	Introduction . . . . .	378
17.2	Drivers of the functional foods market . . . . .	379
17.3	The growth of the functional foods market in the US . . . . .	380
17.4	The regulatory context in the US . . . . .	381
17.5	The potential for functional dairy foods in the US . . . . .	384
17.6	Future trends . . . . .	386
17.7	Sources of further information and advice . . . . .	388
17.8	References . . . . .	388
	<i>Index . . . . .</i>	<i>390</i>